VR Adviser’s Enliven Therapeutics ELVN Stock Holding History

VR Adviser’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.7M	Sell	526,331 -1,200,000	-70%	-$50.9M	0.81%	20
2026 Q1	$67.7M	Sell	1,726,331 -1,500,000	-46%	-$41.6M	2.53%	12
2025 Q4	$49.7M	Hold	3,226,331	–	–	2.45%	13
2025 Q3	$66M	Sell	3,226,331 -800,000	-20%	-$16.1M	3.72%	9
2025 Q2	$80.8M	Hold	4,026,331	–	–	6.05%	4
2025 Q1	$79.2M	Hold	4,026,331	–	–	6.74%	4
2024 Q4	$90.6M	Hold	4,026,331	–	–	6.22%	3
2024 Q3	$103M	Hold	4,026,331	–	–	5.39%	3
2024 Q2	$94.1M	Hold	4,026,331	–	–	5.99%	2
2024 Q1	$70.8M	Buy	4,026,331 +1,071,429	+36%	+$16.4M	3.37%	8
2023 Q4	$40.9M	Hold	2,954,902	–	–	2.8%	10
2023 Q3	$40.4M	Buy	2,954,902 +724,775	+32%	+$12.2M	4.25%	7
2023 Q2	$45.5M	Buy	2,230,127 +15,985	+0.7%	+$323K	7.28%	4
2023 Q1	$48.5M	Buy	+2,214,142	New	+$45M	9.47%	3

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser's ELVN Position: Q2 2026 in Review

VR Adviser reduced its Enliven Therapeutics (ELVN) stake by 70% in Q2 2026, selling an estimated $50.9M and leaving 526,331 shares worth $26.7M. The position accounts for 0.81% of the portfolio, ranked #20.

VR Adviser first reported a position in ELVN in Q1 2023 and has held it in 14 quarters since. The position peaked at $103M in Q3 2024. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

VR Adviser held 526,331 shares of Enliven Therapeutics worth $26.7M as of Q2 2026.
VR Adviser sold 1,200,000 Enliven Therapeutics shares in Q2 2026, an estimated $50.9M.
Enliven Therapeutics made up 0.81% of VR Adviser's portfolio in Q2 2026, its #20 holding.
VR Adviser first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 14 quarters since.
VR Adviser's Enliven Therapeutics position peaked at $103M in Q3 2024.
213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.